4.6 Article

Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study

Journal

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
Volume 13, Issue 3, Pages 1051-1059

Publisher

ELSEVIER
DOI: 10.1016/j.nano.2016.12.001

Keywords

Surface-enhanced Raman spectroscopy; Prostate cancer; Diagnostics

Funding

  1. National Natural Science Foundation of China [81572536, 81672850]
  2. Science and Technology Commission of Shanghai Municipality [14140901700, 16411969800]
  3. Joint Research Foundation for Innovative Medical Technology of Shanghai Shenkang Hospital Development Center [SHDC12015125]
  4. Shanghai Municipal Education Commission [15ZZ058]
  5. Shanghai Municipal Commission of Health and Family Planning [201640247]
  6. Shanghai Municipal EducationCommission-Gaofeng Clinical Medicine Grant Support [20152215]
  7. Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai [PWZxq2014-05]
  8. Innovation Fund for Translational Research of Shanghai Jiao Tong University School of Medicine [15ZH4002]
  9. Renji Medical Research Seed Project [RJZZ13-016]
  10. Incubating Program for clinical Research and Innovation of Renji Hospital Shanghai Jiao Tong University School of Medicine [PYZY 16-008]

Ask authors/readers for more resources

Surface-enhanced Raman spectroscopy (SERS) involving expressed prostatic secretion (EPS) and serum was investigated; the objective was to determine if this approach could distinguish prostate cancer from benign prostatic hyperplasia. A total of 120 SERS spectra for EPS and 96 spectra for serum were gathered from patients within a prospective contemporary biopsy cohort. Significant differences in spectra between prostate cancer and benign prostatic hyperplasia were tentatively assigned to component changes in EPS and serum samples. Principal component analysis and linear discriminate analysis were utilized to evaluate the spectral data for EPS and serum, to build diagnostic algorithms. The leave-one-out cross-validation method was used to validate the diagnostic algorithms; it revealed diagnostic sensitivities of 75% and 60%, specificities of 75% and 76.5%, and accuracies of 75% and 68% for EPS and serum, respectively. The results suggest that EPS and serum SERS analysis could be a potential tool for prostate cancer detection. (C) 2016 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available